BurdEn of NEw Onset Atrial FIbrillation in patienTs With Acute Myocardial Infarction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

774 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To validate the prognostic importance of the burden of new-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) in a prospectively designed hospital-based registry. To characterize those factors that contribute to the progression of post-MI NOAF burden. To establish a prediction model for the risk stratification of patients with NOAF complicating AMI. To explore the clinical usefulness of NOAF burden in guiding the anticoagulation therapy among patients with post-MI NOAF.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

China Acute Myocardial Infarction Registry

NCT01874691

Acute Myocardial Infarction

COMPLETED

Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction

NCT02641184

Coronary Artery Disease Percutaneous Coronary Intervention Acute Myocardial Infarction

UNKNOWN

Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment

NCT03297164

Acute Myocardial Infarction Heart Failure

COMPLETED

Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction

NCT07139860

Acute Myocardial Infarction With ST Elevation Intelligent Management Platform Early Warning

RECRUITING

Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation

NCT03345615

Atrial Fibrillation New Onset Myocardial Infarction

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Our previously designed single-center retrospective cohort study (NCT03533543) suggested that patients with a greater burden of NOAF complicating AMI were challenged by a poor prognosis. In the present study, we aim to design a multicenter, prospective, hospital-based registry to validate the preceding findings. We plan to enroll patients who were admitted for AMI in 9 tertiary medical centers from Shanghai, Henan, and Zhejiang provinces and developed NOAF during the index hospitalization. All eligible patients' demographics, cardiovascular risk factors, comorbidities, laboratory tests, echocardiography data, angiography data, and medications will be collected. NOAF burden is calculated by dividing the total AF duration by the total continuous electronic monitoring (CEM) duration. Other NOAF related characteristics, such as AF pattern, AF frequency, and symptomatic or silent AF, and the longest AF episode duration will also be evaluated. All patients who are discharged alive will be followed for at least 2 years and cardiovascular outcomes will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation New Onset Acute Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low burden of new-onset atrial fibrillation

Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization. Among this subset of patients, those who have a NOAF burden value\<10.87% (previously established) will be divided into the low burden group.

Continuous Electronic Monitor

Intervention Type DEVICE

All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden

High burden of new-onset atrial fibrillation

For patients with NOAF complicating AMI, those who have a NOAF burden value≥10.87% (previously established) will be divided into the high burden group.

Continuous Electronic Monitor

Intervention Type DEVICE

All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous Electronic Monitor

All patients with NOAF complicating AMI will receive at least 5 days electronic monitoring for the evaluation of NOAF burden

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (\>18 years old);
* Patient with AMI (including STEMI and NSTEMI) who developed NOAF during the index hospitalization;
* Patients must have received in-hospital CEM for at least 5 days;
* Patients must give informed consent.

Exclusion Criteria

* Patients with a medical history of pre-existing AF;
* Patients with a medical history of rheumatic valvular disease;
* Patients with a medical history of sick sinus syndrome;
* Patients undergoing emergent coronary artery bypass surgery;
* Patients who suffer malignant tumors with an expected lifetime less than 1 year ;
* Patients who refuse to receive CEM during hospitalization and the data of heart rhythm cannot be retrieved;
* Patients who refuse to receive percutaneous coronary intervention (PCI) or have contraindications for PCI;
* Patients who have died during the index hospitalization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No